AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims

1. (Currently amended) A method for treating an ophthalmologic condition, the method comprising steps of:

providing a contact lens;

providing a pharmaceutical composition suitable for ocular administration, wherein the pharmaceutical composition comprises an effective amount of hyaluronidase and ~~or~~ collagenase;

applying the contact lens to an eye of a patient suffering from an ophthalmologic condition; and

applying the pharmaceutical composition to the eye of the patient.

2. (Currently amended) A method for treating an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:

inducing a change in the corneal power by using molding contact lenses and a pharmaceutical composition by changing the radius of curvature of the anterior surface of both eyes,

wherein the pharmaceutical composition comprises an effective amount of hyaluronidase and ~~or~~ collagenase.

3. (Currently amended) A method for treating an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:

inducing a change in the corneal power by using molding contact lenses and a pharmaceutical composition by changing the radius of curvature of the anterior surface in only one eye,

wherein the pharmaceutical composition comprises an effective amount of hyaluronidase and ~~or~~ collagenase.

4. (Withdrawn and currently amended) A method for the treatment of an ophthalmologic condition by inducing changes in the physiology and anatomy of cornea, the method comprising steps of:

calculating the corneal power considering the sphere (myopia) and cylinder (astigmatism) myopics within a range to be able to correct the near vision without diminishing substantially the far vision;

considering the best axis of astigmatism for each eye that a patient requires for the near vision so that the change induced in the corneal power along with its axis will be that required for the visual system of the patient;

allowing the patient to guide the necessary changes in the corneal power whereby good near vision is obtained;

using the molding contact lenses to change the surface of the cornea; and

administering a pharmaceutical composition to the eye, wherein the composition comprises an effective amount of hyaluronidase and ~~or~~ collagenase.

5. (Withdrawn) The method of claim 4, wherein the sphere (myopia) ranges from -0.100 D to -0.999 D.

6. (Withdrawn) The method of claim 4, wherein the cylinder (astigmatism) ranges from -0.100 D to -0.999 D.

7. (Withdrawn) The method of claim 4, wherein the hypermetropia ranges from +0.100 D to +0.999 D, and the cylinder (astigmatism) ranges from -0.100 D to -0.999 D.

8. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lenses are commercially available.

9. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is not custom made.

10. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is not specially designed for orthokeratology.

11. (Original) The method of claim 1, 2, 3, or 4, wherein the contact lens is an extended wear contact lens.

12. (Currently amended) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition further comprises at least one agent ~~is a combination of agents~~ selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anticlerical agents, anti-viral agents, anti-fungal agents, ~~and~~ anti-inflammatory agents, and lubricants.

13. (Currently Amended) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition further comprises a polymer ~~hyaluronase and collagenase~~.

14. (Currently amended) The method of claim 13, wherein the ~~pharmaceutical composition additionally comprises a vehicle selected from the group consisting of~~ polymer is selected from the group consisting of methylcellulose, cellulose, ~~and~~ polyvinylalcohol, and polyethylene glycol.

15. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is a liquid ~~in the form of eyedrops~~.

16. (Original) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is in the form of a gel.

17. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is hypertonic.

18. (Original) The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is hypotonic.

19. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in correction of the ophthalmologic condition for at least 7 days.

20. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of the ophthalmologic condition for at least 6 months.

21. (Currently amended) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of the ophthalmologic condition for at least 1 year ~~years~~.

22. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 3 diopters of refractive error without surgery.

23. (Original) The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 4 diopters of refractive error without surgery.

24. (Original) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is presbyopia.

25. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is myopia.

26. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is hyperopia.

27. (Withdrawn) The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is astigmatism.

28-38. (Canceled)

39. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 ~~pharmaceutical composition of claim 28,~~ wherein the composition further comprises at least two agents selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anticlerical agents, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants ~~an anesthetic, an antibiotic, an anti-inflammatory agent, an anti-allergic agent, vitamin A, hyaluronidase, carbamide, and a vasoconstrictor~~.

40. (Canceled)

41. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 ~~pharmaceutical composition of claim 28,~~ wherein the composition further comprises at least three agents selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anticlerical agents, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants ~~an anesthetic, an antibiotic, an anti-inflammatory agent, an anti-allergic agent, vitamin A, hyaluronidase, carbamide, a cytokinase, and a vasoconstrictor~~.

42. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4 ~~pharmaceutical composition of claim 28,~~ wherein the composition further comprises at least four agents selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anticlerical agents, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants ~~an anesthetic, an antibiotic, an anti-inflammatory agent, an anticlerical agent, vitamin A, hyaluronidase, carbamide, a cytokinase, and a vasoconstrictor~~.

43. (Withdrawn and currently amended) The method of claim 1, 2, 3, or 4, wherein the composition comprises ~~A pharmaceutical composition comprising:~~ about 0.1% to about 5% hyaluronidase ~~hyalurondiase in the range of 0.1% to 5%~~; about 0.1% to about 6% collagenase ~~in the range of 0.1% to 6%~~; and a polymer ~~vehicle~~ selected from the group consisting of cellulose, methylcellulose, ~~and~~ polyvinylalcohol, and polyethylene glycol.

44. (Withdrawn and currently amended) The method ~~composition~~ of claim 43, wherein the composition is hypotonic.

45. (Withdrawn and currently amended) The method ~~composition~~ of claim 43, wherein the composition is hypertonic ~~hypotonic~~.

46. (Withdrawn and currently amended) The method ~~composition~~ of claim 43, wherein the composition further comprises ~~comprising~~ at least one agent selected from the group consisting of other enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasoconstrictors, anticlerical agents, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants ~~anesthetics, antibiotics, anti-inflammatory agents, vitamin A, carbamide, and vasoconstrictors~~.

47-49. (Canceled)

50. (Withdrawn and currently amended) The method of claim 15, wherein the liquid ~~pharmaceutical composition of claim 28, wherein the composition~~ is in the form of a spray or in the form of eye-drops.

51. (New) The method according to claim 16, wherein the gel is a semi-solid gel.

52. (New) The method according to claims 1, 2, 3 or 4, wherein the contact lens is a gas permeable contact lens.

53. (New) A method for treating presbyopia, the method comprising steps of:

providing a contact lens;

providing a pharmaceutical composition suitable for ocular administration, wherein the pharmaceutical composition comprises an effective amount of hyaluronidase and collagenase;

applying the contact lens to an eye of a patient suffering from presbyopia; and

applying the pharmaceutical composition to the eye of the patient.